Adaptimmune Therapeutics Newsroom

European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading

European equities traded in the US as American depositary receipts opened the week slightly higher Monday morning, rising 0.12% to 1,429.79 on the S&P Europe Select ADR Index. From continental Europe,

MT NewswiresMay 20 11:09 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)

TipRanksMay 20 02:10 ET

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading

European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c

MT NewswiresMay 17 11:06 ET

Adaptimmune Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 158.62% Mizuho $9 → $3 Maintains Buy 08/10/2023 -13.79% Barclays $2 → $1 Maintains Underweight

BenzingaMay 17 07:29 ET

Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating

Adaptimmune Therapeutics (ADAP) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $1 to $4.

MT NewswiresMay 17 06:49 ET

Express News | Adaptimmune Therapeutics PLC : Mizuho Cuts Target Price to $3 From $9

ReutersMay 16 22:56 ET

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta

MT NewswiresMay 16 11:04 ET

Analysts Conflicted on These Healthcare Names: Fortress Biotech (FBIO), GoodRx Holdings (GDRX) and Adaptimmune Therapeutics (ADAP)

TipRanksMay 16 05:10 ET

Adaptimmune Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 22:23 ET · Announcements

TD Cowen Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)

TipRanksMay 15 10:55 ET

Earnings Call Summary | Adaptimmune Therapeutics(ADAP.US) Q1 2024 Earnings Conference

The following is a summary of the Adaptimmune Therapeutics Plc (ADAP) Q1 2024 Earnings Call Transcript:Financial Performance:Adaptimmune has secured up to $125 million in debt financing with Hercules

moomoo AIMay 15 10:45 ET · Conference Call

Adaptimmune Therapeutics Plc (ADAP) Q1 2024 Earnings Call Transcript

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 15 10:07 ET

Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $5

BenzingaMay 15 08:00 ET

Express News | Adaptimmune Therapeutics PLC -Believes Existing Cash, Cash Equivalents and Marketable Securities Will Fund Co’s Current Operations Into Late 2025

ReutersMay 15 07:43 ET

Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Posts Q1 Revenue $5.7M, Vs. Street Est of $17.1M

07:34 AM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Posts Q1 Revenue $5.7M, vs. Street Est of $17.1M

MT NewswiresMay 15 07:34 ET

Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing inf

newsfileMay 15 07:30 ET

Express News | Adaptimmune Therapeutics-First Tranche of $25 Mln Available Upon Closing; Co Will Be Eligible to Draw Additional $25 Mln Subject to Afami-Cel Approval

ReutersMay 15 07:18 ET

Express News | Adaptimmune Therapeutics PLC - Has Entered Into $125 Mln Five-Year, Term Loan Facility With Hercules Capital, Inc

ReutersMay 15 07:17 ET

Express News | Adaptimmune Therapeutics PLC - Secures up to $125 Million Debt Financing With Hercules Capital

ReutersMay 15 07:17 ET

Adaptimmune Secures up to $125 Million Debt Financing With Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approvalPhiladelphia, Pennsylvania and Oxford, United Kindgom--

newsfileMay 15 07:00 ET